tiprankstipranks
Cabaletta Bio, Inc. (CABA)
NASDAQ:CABA
US Market
CABA
Cabaletta Bio
RESEARCH TOOLSreports
Want to see CABA full AI Analyst Report?

Cabaletta Bio (CABA) Stock Forecast & Price Target

1,609 Followers
See the Price Targets and Ratings of:

CABA Analyst Ratings

Strong Buy
7Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Cabaletta
Bio
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CABA Stock 12 Month Forecast

Average Price Target

$15.75
▲(485.50% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Cabaletta Bio in the last 3 months. The average price target is $15.75 with a high forecast of $30.00 and a low forecast of $4.00. The average price target represents a 485.50% change from the last price of $2.69.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","31":"$31","7.75":"$7.75","15.5":"$15.5","23.25":"$23.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,7.75,15.5,23.25,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,4.781538461538462,6.883076923076922,8.984615384615385,11.086153846153845,13.187692307692306,15.289230769230768,17.39076923076923,19.49230769230769,21.59384615384615,23.69538461538461,25.796923076923076,27.898461538461536,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,3.6853846153846153,4.690769230769231,5.696153846153846,6.701538461538462,7.706923076923077,8.712307692307691,9.717692307692307,10.723076923076922,11.728461538461538,12.733846153846153,13.739230769230769,14.744615384615383,{"y":15.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,2.7815384615384615,2.8830769230769233,2.9846153846153847,3.086153846153846,3.187692307692308,3.289230769230769,3.390769230769231,3.4923076923076923,3.5938461538461537,3.6953846153846155,3.796923076923077,3.8984615384615386,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.31,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.61,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.94,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.67,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.99,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$30.00Average Price Target$15.75Lowest Price Target$4.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CABA
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
―
Buy
―
Reiterated
06/08/26
Analysts' Top Healthcare Picks: Alto Neuroscience, Inc. (ANRO), Anixa Biosciences (ANIX)
Cantor Fitzgerald Analyst forecast on CABA
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$30
Buy
1015.24%
Upside
Reiterated
06/06/26
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR), Cabaletta Bio (NASDAQ: CABA) and Hinge Health, Inc. Class A (NYSE: HNGE)
William Blair Analyst forecast on CABA
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Cabaletta Bio (NASDAQ: CABA) and Tenaya Therapeutics (NASDAQ: TNYA)
TD Cowen Analyst forecast on CABA
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Cabaletta Bio (NASDAQ: CABA) and Vir Biotechnology (NASDAQ: VIR)
Morgan Stanley Analyst forecast on CABA
Michael Ulz
Morgan Stanley
Morgan Stanley
$13
Buy
383.27%
Upside
Reiterated
06/03/26
Buy Rating Reaffirmed on Robust Rese‑cel Autoimmune Data; $13 Price Target Reiterated as Cabaletta Advances Toward Commercialization
Wells Fargo Analyst forecast on CABA
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$2→$4
Hold
48.70%
Upside
Assigned
05/15/26
Wells Fargo Gives a Hold Rating to Cabaletta Bio (CABA)
Guggenheim Analyst forecast on CABA
Yatin Suneja
Guggenheim
Guggenheim
$16
Buy
494.80%
Upside
Reiterated
05/15/26
Cabaletta Bio (CABA) Receives a Buy from Guggenheim
Jefferies Analyst forecast on CABA
Roger Song
Jefferies
Jefferies
$14
Buy
420.45%
Upside
Reiterated
03/23/26
Analysts' Top Healthcare Picks: IDEAYA Biosciences (IDYA), Cabaletta Bio (CABA)
Evercore ISI Analyst forecast on CABA
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$4
Hold
48.70%
Upside
Reiterated
12/17/25
Evercore ISI Reaffirms Their Hold Rating on Cabaletta Bio (CABA)
Citi Analyst forecast on CABA
Samantha Semenkow
Citi
Citi
$10
Buy
271.75%
Upside
Reiterated
10/10/25
Promising Early Data from Cabaletta Bio's Rese-cel Therapy Suggests Significant Potential in Autoimmune Treatment
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CABA
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
―
Buy
―
Reiterated
06/08/26
Analysts' Top Healthcare Picks: Alto Neuroscience, Inc. (ANRO), Anixa Biosciences (ANIX)
Cantor Fitzgerald Analyst forecast on CABA
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$30
Buy
1015.24%
Upside
Reiterated
06/06/26
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR), Cabaletta Bio (NASDAQ: CABA) and Hinge Health, Inc. Class A (NYSE: HNGE)
William Blair Analyst forecast on CABA
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Cabaletta Bio (NASDAQ: CABA) and Tenaya Therapeutics (NASDAQ: TNYA)
TD Cowen Analyst forecast on CABA
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Cabaletta Bio (NASDAQ: CABA) and Vir Biotechnology (NASDAQ: VIR)
Morgan Stanley Analyst forecast on CABA
Michael Ulz
Morgan Stanley
Morgan Stanley
$13
Buy
383.27%
Upside
Reiterated
06/03/26
Buy Rating Reaffirmed on Robust Rese‑cel Autoimmune Data; $13 Price Target Reiterated as Cabaletta Advances Toward Commercialization
Wells Fargo Analyst forecast on CABA
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$2→$4
Hold
48.70%
Upside
Assigned
05/15/26
Wells Fargo Gives a Hold Rating to Cabaletta Bio (CABA)
Guggenheim Analyst forecast on CABA
Yatin Suneja
Guggenheim
Guggenheim
$16
Buy
494.80%
Upside
Reiterated
05/15/26
Cabaletta Bio (CABA) Receives a Buy from Guggenheim
Jefferies Analyst forecast on CABA
Roger Song
Jefferies
Jefferies
$14
Buy
420.45%
Upside
Reiterated
03/23/26
Analysts' Top Healthcare Picks: IDEAYA Biosciences (IDYA), Cabaletta Bio (CABA)
Evercore ISI Analyst forecast on CABA
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$4
Hold
48.70%
Upside
Reiterated
12/17/25
Evercore ISI Reaffirms Their Hold Rating on Cabaletta Bio (CABA)
Citi Analyst forecast on CABA
Samantha Semenkow
Citi
Citi
$10
Buy
271.75%
Upside
Reiterated
10/10/25
Promising Early Data from Cabaletta Bio's Rese-cel Therapy Suggests Significant Potential in Autoimmune Treatment
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cabaletta Bio

3 Months
Douglas TsaoH.C. Wainwright
Success Rate
10/21 ratings generated profit
48%
Average Return
-2.27%
Copying Douglas Tsao's trades and holding each position for 3 Months would result in 47.62% of your transactions generating a profit, with an average return of -2.27% per trade.
1 Year
Sami CorwinWilliam Blair
Success Rate
10/21 ratings generated profit
48%
Average Return
+0.89%
Copying Sami Corwin's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +0.89% per trade.
2 Years
Sami CorwinWilliam Blair
Success Rate
11/21 ratings generated profit
52%
Average Return
+3.96%
Copying Sami Corwin's trades and holding each position for 2 Years would result in 52.38% of your transactions generating a profit, with an average return of +3.96% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CABA Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
7
12
12
9
3
Buy
7
6
7
5
3
Hold
1
2
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
20
20
15
6
In the current month, CABA has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CABA average Analyst price target in the past 3 months is 15.75.
Each month's total comprises the sum of three months' worth of ratings.

CABA Financial Forecast

CABA Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.
No data currently available

CABA Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

CABA Stock Forecast FAQ

What is CABA’s average 12-month price target, according to analysts?
Based on analyst ratings, Cabaletta Bio, Inc.’s 12-month average price target is 15.75.
    What is CABA’s upside potential, based on the analysts’ average price target?
    Cabaletta Bio, Inc. has 485.50% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CABA a Buy, Sell or Hold?
          Cabaletta Bio, Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Cabaletta Bio, Inc.’s price target?
            The average price target for Cabaletta Bio, Inc. is 15.75. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $30.00 ,the lowest forecast is $4.00. The average price target represents 485.50% Increase from the current price of $2.69.
              What do analysts say about Cabaletta Bio, Inc.?
              Cabaletta Bio, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of CABA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.